Anxiolytic Mechanisms
The neurobiology of anxiety and how benzodiazepines, buspirone, SSRIs, and emerging agents reduce pathological anxiety.
Neurobiology of Anxiety
Anxiety involves hyperactivity of the amygdala fear circuit, excessive noradrenergic tone from the locus coeruleus, and insufficient GABAergic and serotonergic inhibition. The HPA axis (CRF -> ACTH -> cortisol) is chronically activated in anxiety disorders, contributing to physiological stress responses.
Benzodiazepines
Benzodiazepines (diazepam, lorazepam, alprazolam, clonazepam) bind the alpha/gamma interface of GABA-A receptors, increasing chloride channel opening frequency. Effects are rapid (minutes to hours), providing acute relief.
Limitations:
- Tolerance and physical dependence develop with chronic use
- Withdrawal seizures with abrupt discontinuation
- Cognitive impairment, sedation, and fall risk in elderly
- Abuse potential, especially with short-acting agents (alprazolam)
- Flumazenil reverses benzodiazepine effects but can precipitate seizures in dependent patients
Buspirone
Buspirone is a 5-HT1A partial agonist with anxiolytic properties. It has no sedation, no abuse potential, and no cross-tolerance with benzodiazepines. The 2-4 week onset delay limits its use for acute anxiety. It is effective for generalized anxiety disorder (GAD) but not panic disorder.
SSRIs and SNRIs
SSRIs (escitalopram, sertraline) and SNRIs (venlafaxine, duloxetine) are first-line for most anxiety disorders including GAD, panic disorder, social anxiety, and PTSD. Their anxiolytic effect takes 2-6 weeks and involves serotonergic modulation of amygdala circuits. Initial paradoxical anxiety may occur in the first 1-2 weeks.
Other Agents
- Pregabalin -- alpha-2-delta calcium channel ligand; approved for GAD in Europe; reduces excitatory neurotransmitter release
- Hydroxyzine -- H1 antihistamine; sedating anxiolytic for short-term use
- Beta-blockers -- propranolol blocks peripheral sympathetic symptoms (tremor, tachycardia) in performance anxiety; no central anxiolytic effect
- Gabapentin -- off-label for social anxiety; similar mechanism to pregabalin
Emerging Targets
GABA-A positive allosteric modulators selective for alpha-2/3 subunits aim to provide anxiolysis without alpha-1-mediated sedation. CRF1 receptor antagonists and glutamate modulators are in development.
Key Takeaways
- SSRIs/SNRIs are first-line for chronic anxiety disorders despite delayed onset
- Benzodiazepines provide rapid relief but carry dependence and cognitive risks
- Buspirone is a non-sedating alternative for GAD with no abuse potential
- Subtype-selective GABA-A modulators may offer anxiolysis without sedation